Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$51.70M
EBITDA Margin
-36.23%
TTM Avg
-36.23%
3Y Avg
-36.23%
5Y Avg
-36.23%
Market Cap
$53.80M
EBITDA Margin
-5927.25%
TTM Avg
-3470.39%
3Y Avg
-2050.54%
5Y Avg
-1465.25%
Market Cap
$51.36M
EBITDA Margin
-2290.88%
TTM Avg
-3688.53%
3Y Avg
-3688.53%
5Y Avg
-3177.84%
Market Cap
$50.96M
EBITDA Margin
-9115.35%
TTM Avg
-8798.34%
3Y Avg
-6751.54%
5Y Avg
-5839.94%
Market Cap
$50.80M
EBITDA Margin
-61570.00%
TTM Avg
-181077.86%
3Y Avg
-90538.93%
5Y Avg
-60359.29%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NOMAD Power Solutions, Inc. (NMAD) | $52.47M | N/A | N/A | N/A | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $52.05M | 20.40% | 19.12% | 4.66% | 12.12% |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $51.70M | -36.23% | -36.23% | -36.23% | -36.23% |
| ImageneBio Inc (IMA)vs › | $53.80M | -5927.25% | -3470.39% | -2050.54% | -1465.25% |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Rani Therapeutics Holdings, Inc. (RANI)vs › | $51.36M | -2290.88% | -3688.53% | -3688.53% | -3177.84% |
| Envoy Medical, Inc. (COCH)vs › | $50.96M | -9115.35% | -8798.34% | -6751.54% | -5839.94% |
| INmune Bio, Inc. (INMB)vs › | $50.80M | -61570.00% | -181077.86% | -90538.93% | -60359.29% |
| Clene Inc. (CLNN)vs › | $51.56M | -10794.00% | -9994.66% | -8986.60% | -8678.68% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
